Does Vascepa Cause Serious Side Effects?
Vascepa (icosapent ethyl), used to lower triglycerides and reduce cardiovascular risk in high-risk patients, has reported serious side effects. The FDA label lists risks including severe allergic reactions, bleeding, heart rhythm problems, and pancreatitis.[1] These occur in a small percentage of users but can be life-threatening.
What Serious Side Effects Are Listed?
Key serious risks from clinical data and post-marketing reports:
- Atrial fibrillation or flutter: Occurred in 5% of Vascepa patients vs. 3.9% on placebo in the REDUCE-IT trial; higher risk with concurrent use of other rhythm-altering drugs.[1][2]
- Bleeding events: Including gastrointestinal hemorrhage (0.8% vs. 0.3% placebo); risk rises with anticoagulants like warfarin.[1]
- Allergic reactions: Anaphylaxis or angioedema, sometimes severe enough to require hospitalization.[1]
- Pancreatitis: Rare but possible due to triglyceride-lowering effects.[1]
- Hemorrhagic stroke: Increased incidence in trials (0.5% vs. 0.2% placebo).[2]
Most patients tolerate it well, but monitoring is advised for those with bleeding disorders or on blood thinners.
How Common Are These in Real-World Use?
In REDUCE-IT (8,179 patients), serious cardiovascular events dropped overall, but specific risks like atrial fibrillation led to more discontinuations (5.6% vs. 4.4% placebo).[2] Post-approval data shows low incidence—under 1% for most severe events—but underreporting is possible.
Who Is at Higher Risk?
Patients over 65, those with prior heart issues, or on antiplatelets/anticoagulants face elevated risks. The label warns against use in active pancreatitis or hypersensitivity to fish oil components.[1] Liver function tests are recommended before starting.
What Do Patients Report Online?
User reviews on Drugs.com note occasional severe fatigue, muscle pain, or bleeding, but many report no issues. About 4% rate it negatively due to side effects like heart palpitations.[3] Always consult a doctor for personal risk.
How Does Vascepa Compare to Alternatives?
Compared to Lovaza (another icosapent ethyl-fenofibrate combo), Vascepa has purer EPA, potentially fewer GI issues but similar bleeding risks. Statins like atorvastatin pair with it but amplify muscle-related events.[2]
[1]: FDA Vascepa Label
[2]: REDUCE-IT Trial (NEJM)
[3]: Drugs.com Vascepa Reviews